DE60221115D1 - Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose - Google Patents

Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose

Info

Publication number
DE60221115D1
DE60221115D1 DE60221115T DE60221115T DE60221115D1 DE 60221115 D1 DE60221115 D1 DE 60221115D1 DE 60221115 T DE60221115 T DE 60221115T DE 60221115 T DE60221115 T DE 60221115T DE 60221115 D1 DE60221115 D1 DE 60221115D1
Authority
DE
Germany
Prior art keywords
methods
compositions
fibronectin fragments
cancer diagnosis
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60221115T
Other languages
English (en)
Other versions
DE60221115T2 (de
Inventor
Donna Livant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan filed Critical University of Michigan
Application granted granted Critical
Publication of DE60221115D1 publication Critical patent/DE60221115D1/de
Publication of DE60221115T2 publication Critical patent/DE60221115T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60221115T 2001-01-18 2002-01-15 Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose Expired - Lifetime DE60221115T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76549601A 2001-01-18 2001-01-18
US765496 2001-01-18
PCT/US2002/001189 WO2002057786A2 (en) 2001-01-18 2002-01-15 Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer

Publications (2)

Publication Number Publication Date
DE60221115D1 true DE60221115D1 (de) 2007-08-23
DE60221115T2 DE60221115T2 (de) 2008-03-13

Family

ID=25073705

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60221115T Expired - Lifetime DE60221115T2 (de) 2001-01-18 2002-01-15 Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose

Country Status (5)

Country Link
EP (1) EP1388013B1 (de)
AT (1) ATE366936T1 (de)
CA (1) CA2435320C (de)
DE (1) DE60221115T2 (de)
WO (1) WO2002057786A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200500871A1 (ru) 2002-11-25 2006-04-28 Атеньюон, Ллк Пептиды, ингибирующие ангиогенез, миграцию клеток, инвазию клеток и пролиферацию клеток, композиции и их применение
US20060024757A1 (en) 2004-07-30 2006-02-02 Robert Hussa Detection of oncofetal fibronectin for selection of concepti
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
EP2589668A1 (de) 2006-06-14 2013-05-08 Verinata Health, Inc Analyse seltener Zellen mittels Probentrennung und DNA-Etiketten
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
EP2029779A4 (de) 2006-06-14 2010-01-20 Living Microsystems Inc Verwendung hoch paralleler snp-genotypisierung zur fötalen diagnose
EP2058662A1 (de) * 2007-10-17 2009-05-13 Koninklijke Philips Electronics N.V. Diagnose von Erkrankungen durch Messung des zellenvermittelten Abbaus der extrazellulären Matrix
PT2562268T (pt) 2008-09-20 2017-03-29 Univ Leland Stanford Junior Diagnóstico não invasivo de aneuploidia fetal por sequenciação
EP2182356A1 (de) * 2008-11-04 2010-05-05 Koninklijke Philips Electronics N.V. Verwendung von Serumproben zur Diagnose von Prostatakrebs durch Messen der Monozyt-Migration
DK2836843T3 (da) * 2012-04-13 2020-08-24 Prediction Biosciences Sas Hurtigtest til cellulært fibronektin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894326A (en) * 1986-04-09 1990-01-16 Fred Hutchinson Cancer Research Center Monoclonal antibody defining oncofetal structure of fibronectin
US5840514A (en) * 1996-11-21 1998-11-24 The Regents Of The University Of Michigan Methods of testing cancer and anticancer drugs

Also Published As

Publication number Publication date
DE60221115T2 (de) 2008-03-13
EP1388013B1 (de) 2007-07-11
ATE366936T1 (de) 2007-08-15
CA2435320C (en) 2008-06-03
WO2002057786A2 (en) 2002-07-25
CA2435320A1 (en) 2002-07-25
EP1388013A2 (de) 2004-02-11
WO2002057786A3 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
DK2258872T3 (da) Genekspressionsprofilering i biopsier af tumorvæv
EP2130926A3 (de) Phagen-Mikroarray-Profilerstellung der humoralen Antwort auf Erkrankungen
DE602006015966D1 (de) Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
EP2230319A3 (de) Genexpressionsmarker für Brustkrebsprognose
ATE476908T1 (de) System und diagnoseverfahren zur optischen detektion von verdächtigen stellen einer gewebeprobe
ATE527552T1 (de) Mr-darstellungsverfahren zur diskriminierung zwischen gesundem und tumorgewebe
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP1892306A3 (de) Verfahren und Kit zur Untersuchung von Krebs
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
WO2003087831A3 (en) Proteins involved in breast cancer
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
DE60221115D1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
WO2004073657A3 (en) Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
DE60032784D1 (de) Markerproteine für prostatakrebs
AU3392901A (en) Proteins
DE60207288D1 (de) Gewebespezifische fluoreszierende chelate
WO2004104591A3 (en) Improvements to gamma delta t cell-mediated therapy
WO2003105773A3 (en) MUTATIONS OF PDGFRA ACTIVATED AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
WO2003069553A3 (en) Method of image analysis
ATE306668T1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker

Legal Events

Date Code Title Description
8364 No opposition during term of opposition